vipor: a multi-targeted therapy for the treatment of r/r dlbcl
Published 9 months ago • 175 plays • Length 2:15Download video MP4
Download video MP3
Similar videos
-
2:39
the role of bispecific antibodies in the treatment landscape for r/r dlbcl
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:27
tp53-aberrant mcl: challenges and treatment approaches
-
0:42
targeted therapies for dlbcl treatment
-
1:20
improving patient outcomes in ctcl: clinical collaboration and novel agents
-
2:34
sequencing of therapies in patients with r/r cll
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl
-
9:25
mgus diagnosis: a step-by-step approach
-
3:52
maintenance therapy with revumenib following allosct in kmt2ar and npm1-mutated acute leukemias
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
1:18
preventing and managing infections in patients with lymphoma treated with immunosuppressive therapy
-
2:45
continuity of care for patients with hematological predispositions to aml
-
1:38
the use of golcadomide in combination with r-chop for the treatment of aggressive b-cell lymphomas
-
2:04
the importance of individualizing treatment approaches in hl to improve patient outcomes
-
1:59
assessing if a patient with dlbcl is responding to treatment using pet-ct and novel assays
-
3:04
outpatient monitoring following car-t and bsab treatment for patients with lymphoma and mm
-
2:15
updates from the phase ii aern trial: nivolumab and radiotherapy for the treatment of r/r hl
-
6:02
predicting treatment outcomes in patients with r/r chl with ctdna and pet
-
1:54
navigating regulatory challenges in developing and approving therapies for rare lymphomas
-
1:12
optimizing treatment in hodgkin lymphoma